Recommendation for CardioQ

Deltex Medical Group PLC
25 July 2007


                            Deltex Medical Group plc

             Use of CardioQTM recommended for all London hospitals


25 July 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the
UK's leading haemodynamic monitoring company, notes that a major report into the
future of healthcare in London has recommended increased use of oesophageal
Doppler monitoring.

The Planned Care Clinical Working Group was established to report into the
Healthcare for London Review. This review was led by Sir Ara Darzi, who was
recently appointed a minister at the Department of Health, with responsibility
for conducting the national NHS Next Stage review.

The report draws on treatment methodologies established in Australia and
recommends (recommendation 10) that these are established across London:

'When integrating the Melbourne model of treatment into a care package with
other (cheap) evidence-based interventions (such as use of perioperative Doppler
studies and early feeding/topping up of fluids) quality of care is further
improved and length of stay reduced. Thus, seven randomised trials have shown
simple use of cheap Doppler technology to reduce length of stay consistently by
two to three days in elective intra-abdominal surgery. It is recommended that
physician and intensive care management be better integrated with surgical
practice, and that appropriate evidence-based care bundles be rapidly
established and implemented London-wide.'

The full report can be viewed at http://www.healthcareforlondon.nhs.uk/
framework_for_action.asp under the link to 'Planned Care'.

Commenting on the report's recommendation, Deltex Medical's Chief Executive,
Andy Hill said:

'The London Planned Care report puts wide-scale use of the CardioQ exactly where
it should be: at the heart of improving healthcare quality and efficiency.'


For further information, please contact:-

Deltex Medical Group plc             01243 774 837
Nigel Keen, Chairman                 [e-mail]
Andy Hill, Chief Executive           [e-mail]
Ewan Phillips, Finance Director      [e-mail]

Gavin Anderson & Company             0207 554 1400
Deborah Walter                       [e-mail]
Robert Speed                         [e-mail]

Charles Stanley Securities           020 7149 6457
Philip Davies                        [e-mail]
Russell Cook                         [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQTM monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ, to optimise the amount of
circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQTM is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange